Aridis Pharmaceuticals, Inc

(NASDAQ:ARDS)

Latest On Aridis Pharmaceuticals, Inc (ARDS):

Date/Time Type Description Signal Details
2023-03-13 10:23 ESTNewsAridis stock surges ~35% as lung disease drug AR-501 meets main goal in mid-stage studyN/A
2023-01-26 17:59 ESTNewsAridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumoniaN/A
2022-12-12 09:44 ESTNewsAridis wins $4.85M equity investment from Cystic Fibrosis FoundationN/A
2022-11-22 16:27 ESTNewsAridis Pharmaceuticals GAAP EPS of -$0.47 misses by $0.30, revenue of $0.4M misses by $7.07MN/A
2022-09-28 00:08 ESTNewsAridis Pharmaceuticals gains on withdrawal of public offering of common stockN/A
2022-09-26 16:17 ESTNewsAridis Pharmaceuticals announces proposed public stock offering; shares down ~30%N/A
2022-08-16 21:33 ESTNewsAridis Pharmaceuticals GAAP EPS of -$0.45, revenue of $0.29MN/A
2022-05-17 03:37 ESTNewsAridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82MN/A
2022-04-01 19:26 ESTNewsAridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33MN/A
2022-02-17 10:55 ESTNewsAridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal modelsN/A
2022-01-27 10:58 ESTNewsAridis wins funding from Gates Foundation to test inhalational COVID-19 antibodiesN/A
2021-12-21 16:52 ESTNewsAridis Pharma nearly doubles after its antibody cocktail retains effectiveness against Omicron variantN/A
2021-11-11 01:35 ESTNewsAridis Pharmaceuticals EPS misses by $1.44, beats on revenueN/A
2021-10-12 20:39 ESTNewsWarning: ARDS is at high risk of performing badlyN/A
2021-08-12 12:45 ESTNewsAridis Pharmaceuticals EPS beats by $0.14, misses on revenueN/A
2021-07-20 19:29 ESTNewsAridis surges 36% after COVID cocktail neutralizes delta variant in preclinical modelN/A
2021-07-20 19:28 ESTNewsAridis falls ~20%, day after surging following COVID antibody cocktail dataN/A
2021-07-20 19:26 ESTNewsAridis inks suvratoxumab licensing agreement with AstraZeneca for up to $126MN/A
2021-03-30 21:24 ESTNewsAridis Pharmaceuticals EPS in-lineN/A
2021-03-08 17:53 ESTNewsAridis brokers agreement with Kermode for zoonotic viruses, shares surge 9%N/A
2021-02-23 10:23 ESTNewsAridis Pharma's dual antibody cocktail could neutralize COVID-19 variantsN/A
2020-12-17 11:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.6 to $17.2.Neutral
2020-12-13 03:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 11:12 ESTFinancialsCompany financials have been released.Neutral
2020-11-23 15:10 ESTFinancialsCompany financials have been released.Neutral
2020-11-21 14:59 ESTNewsAridis Pharmaceuticals EPS misses by $0.02N/A
2020-11-15 11:14 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:05 ESTFinancialsCompany financials have been released.Neutral
2020-10-31 10:57 ESTNewsAridis Pharmaceuticals (ARDS) Investor Presentation - SlideshowN/A
2020-10-19 15:32 ESTNewsAridis Pharma up 7% on potential inhaled therapy for COVID-19N/A
2020-10-14 06:44 ESTNewsAridis Pharmaceuticals to raise $8.5M in direct offeringN/A
2020-09-26 04:17 ESTFinancialsCompany financials have been released.Neutral
2020-09-08 06:35 ESTNewsAridis Pharma on go with mid-stage study of AR-501 in cystic fibrosisN/A
2020-08-13 12:09 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 09:56 ESTNewsAridis Pharmaceuticals EPS beats by $0.27, beats on revenueN/A
2020-07-31 00:11 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 12:08 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:16 ESTFinancialsCompany financials have been released.Neutral
2020-06-22 19:58 ESTNewsAridis's AR-501 shows positive effect in early-stage studyN/A
2020-06-02 16:17 ESTEarnings EstimateAn EPS average of -$0.80 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-02 16:17 ESTAnalyst RatingThe Analyst Target Price has increased from $17.8 to $18.6.Buy
2020-05-31 16:34 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 20:06 ESTFinancialsCompany financials have been released.Neutral
2020-05-15 04:09 ESTFinancialsCompany financials have been released.Neutral
2020-05-13 07:25 ESTNewsAridis Pharmaceuticals EPS misses by $0.19N/A
2020-05-04 22:53 ESTNewsAridis Pharm enrolls first COVID-19 patient in late-stage AR-301 trialN/A
2020-05-03 08:10 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 00:07 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 02:42 ESTNewsStifel likes Alector and Denali in premarket analyst actionN/A
2020-04-11 02:30 ESTNewsKey events next week - healthcareN/A

About Aridis Pharmaceuticals, Inc (ARDS):

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.

ARDS Quotes by TradingView

See Advanced Chart

General

  • Name Aridis Pharmaceuticals, Inc
  • Symbol ARDS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 25
  • Fiscal Year EndDecember
  • IPO Date2018-08-10
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.aridispharma.com
View More

Valuation

  • Trailing PE 2.83
  • Price/Sales (Trailing 12 Mt.) 63.88
  • Price/Book (Most Recent Quarter) 5.4
  • Enterprise Value Revenue 66.57
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.75
  • Operating Margin -2227%
  • Return on Assets -60%
  • Revenue 1000000
  • Earnings Per Share -$4.19
  • Revenue Per Share $0.11
  • Gross Profit -23061000
  • Quarterly Earnings Growth -100%
View More

Highlights

  • Market Capitalization 65.13 million
  • EBITDA -27875000
  • Analyst Target Price $17.2
  • Book Value Per Share $0.99
View More

Share Statistics

  • Shares Outstanding 10.07 million
  • Shares Float 6.36 million
  • % Held by Insiders 3703%
  • % Held by Institutions 1.84%
  • Shares Short 8468
  • Shares Short Prior Month 12255
  • Short Ratio 0.27
View More

Technicals

  • Beta 0.13
  • 52 Week High $10
  • 52 Week Low $4.35
  • 50 Day Moving Average 6.91
  • 200 Day Moving Average 6.96
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aridis Pharmaceuticals, Inc (ARDS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aridis Pharmaceuticals, Inc (ARDS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-20$N/A-$0.65-$0.661.52%
2020-06-302020-08-11$N/A-$0.47-$0.7739.16%
2020-03-312020-04-08$N/A-$0.62-$0.8123.22%
2019-12-312020-03-26$N/A-$0.63-$0.8122.22%
2019-09-302019-11-13$N/A-$0.87-$0.870%
2019-06-302019-08-12$N/A-$1.03-$0.82-26.12%
2019-03-312019-05-14$1.02 million-$0.99-$0.87-14.23%
2018-12-312019-03-28$1.39 million-$0.67-$1.4252.78%
2018-09-302018-11-13$1.02 million-$0.98-$1.0910.09%
2018-06-302018-09-26$22000-$0.24-$1.2680.95%

Aridis Pharmaceuticals, Inc (ARDS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A 4.92 million 4.3 million 6.01 million
Income Before Tax N/A N/A -6.5 million -5.65 million -7.59 million
Selling General Administrative N/A N/A 1.64 million 1.39 million 1.38 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A -6.47 million -5.6 million -7.4 million
Operating Income N/A N/A -6.56 million -5.69 million -7.4 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A -9000 -41000 -192000
Net Income From Continuing Operations N/A N/A -6.5 million -5.65 million -7.59 million
Net Income Applicable to Common Shares -5.79 million -4.22 million N/A -5.65 million -7.59 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -13000 -121000 N/A
Change to Liabilities -478000 -270000 N/A 9.14 million 10.78 million
Total Cash Flow from Investing Activities -16000 -4000 N/A -121000 -26000
Net Borrowings N/A 715000 N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 14000 18000 4.97 million
Change to Operating Activities -967000 -339000 N/A -434000 -1.23 million
Change in Cash N/A N/A -4.57 million 3.57 million 8.81 million
Total Cash from Operating Activities -5.58 million -5.22 million -4.57 million 3.67 million 3.87 million
Depreciation N/A N/A 84000 85000 87000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A 1000000
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 562000 523000 N/A 530000 817000
Capital Expenditures N/A N/A 13000 121000 26000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A 24.38 million 24.33 million 25.59 million
Total Stockholder Equity N/A N/A -2.38 million 3.64 million 8.78 million
Other Current Liabilities N/A N/A N/A N/A 2.54 million
Total Assets N/A N/A 22.01 million 27.97 million 34.37 million
Common Stock -11298000 1000 N/A 1000 1000
Other Current Assets 5.89 million N/A N/A N/A N/A
Retained Earnings N/A -111.49 million -107.27 million -100.77 million -95.12 million
Other Liabilities 23.4 million 4.94 million N/A 5 million 17.06 million
Other Assets N/A 1.09 million N/A 1.08 million 2.12 million
Cash N/A N/A 16.32 million 20.9 million 17.33 million
Total Current Liabilities N/A N/A 19.44 million 19.33 million 8.53 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment N/A 845000 N/A 1.01 million 1.08 million
Total Current Assets 12.11 million N/A 19.98 million 25.84 million 31.09 million
Long Term Investments N/A N/A N/A 9000 50000
Net Tangible Assets -11.3 million -6.1 million N/A 3.6 million 8.74 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable N/A N/A 1.97 million 1.76 million 3.13 million

Aridis Pharmaceuticals, Inc (ARDS) Chart:

Aridis Pharmaceuticals, Inc (ARDS) News:

Below you will find a list of latest news for Aridis Pharmaceuticals, Inc (ARDS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aridis Pharmaceuticals, Inc (ARDS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ARDS Trades:

Date Shares Price
Jun 13, 2022 7:35 PM EST100$1.465
Jun 13, 2022 7:47 PM EST100$1.45
Jun 13, 2022 7:56 PM EST8$1.44
Jun 13, 2022 7:57 PM EST100$1.45
Jun 13, 2022 7:57 PM EST92$1.44

Aridis Pharmaceuticals, Inc (ARDS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920077469/0001104659-20-077469-index.htm
2018-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1614067/000000000018023401/0000000000-18-023401-index.htm
2018-08-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1614067/000000000018024512/0000000000-18-024512-index.htm
2019-08-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1614067/000000000019012776/0000000000-19-012776-index.htm
2019-08-13DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1614067/000091205719000346/0000912057-19-000346-index.htm
2018-08-06S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1614067/000104746918005409/0001047469-18-005409-index.htm
2018-08-09S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1614067/000104746918005552/0001047469-18-005552-index.htm
2018-08-15424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1614067/000104746918005638/0001047469-18-005638-index.htm
2019-03-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1614067/000104746919001721/0001047469-19-001721-index.htm
2019-07-02DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1614067/000104746919003978/0001047469-19-003978-index.htm
2019-09-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1614067/000104746919004939/0001047469-19-004939-index.htm
2020-04-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1614067/000104746920002189/0001047469-20-002189-index.htm
2020-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1614067/000104746920002371/0001047469-20-002371-index.htm
2020-10-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1614067/000104746920005194/0001047469-20-005194-index.htm
2018-07-31CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465918048393/0001104659-18-048393-index.htm
2018-08-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465918049634/0001104659-18-049634-index.htm
2018-08-08S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1614067/000110465918050217/0001104659-18-050217-index.htm
2018-08-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051001/0001104659-18-051001-index.htm
2018-08-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051002/0001104659-18-051002-index.htm
2018-08-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051004/0001104659-18-051004-index.htm
2018-08-138-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1614067/000110465918051429/0001104659-18-051429-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051563/0001104659-18-051563-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051565/0001104659-18-051565-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051566/0001104659-18-051566-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051568/0001104659-18-051568-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051569/0001104659-18-051569-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051570/0001104659-18-051570-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051571/0001104659-18-051571-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051572/0001104659-18-051572-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051573/0001104659-18-051573-index.htm
2018-08-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918051633/0001104659-18-051633-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918054503/0001104659-18-054503-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918058345/0001104659-18-058345-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918058624/0001104659-18-058624-index.htm
2018-09-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465918058727/0001104659-18-058727-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918066525/0001104659-18-066525-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918067925/0001104659-18-067925-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465918068491/0001104659-18-068491-index.htm
2018-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918071356/0001104659-18-071356-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918072393/0001104659-18-072393-index.htm
2018-12-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918072394/0001104659-18-072394-index.htm
2018-12-124/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465918072488/0001104659-18-072488-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465918073102/0001104659-18-073102-index.htm
2019-02-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919011092/0001104659-19-011092-index.htm
2019-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919014626/0001104659-19-014626-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919018257/0001104659-19-018257-index.htm
2019-04-1910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1614067/000110465919022429/0001104659-19-022429-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465919029303/0001104659-19-029303-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919029327/0001104659-19-029327-index.htm
2019-06-1210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1614067/000110465919034957/0001104659-19-034957-index.htm
2019-06-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919035944/0001104659-19-035944-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919037920/0001104659-19-037920-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919040253/0001104659-19-040253-index.htm
2019-07-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919042632/0001104659-19-042632-index.htm
2019-08-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919043489/0001104659-19-043489-index.htm
2019-08-128-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045302/0001104659-19-045302-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045310/0001104659-19-045310-index.htm
2019-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465919045315/0001104659-19-045315-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045923/0001104659-19-045923-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045979/0001104659-19-045979-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045980/0001104659-19-045980-index.htm
2019-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919045981/0001104659-19-045981-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047873/0001104659-19-047873-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047874/0001104659-19-047874-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047875/0001104659-19-047875-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047876/0001104659-19-047876-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047877/0001104659-19-047877-index.htm
2019-08-294/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047878/0001104659-19-047878-index.htm
2019-08-294/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047879/0001104659-19-047879-index.htm
2019-08-294/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047880/0001104659-19-047880-index.htm
2019-08-294/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047881/0001104659-19-047881-index.htm
2019-08-293/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919047930/0001104659-19-047930-index.htm
2019-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919048359/0001104659-19-048359-index.htm
2019-09-03S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1614067/000110465919048438/0001104659-19-048438-index.htm
2019-09-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1614067/000110465919048474/0001104659-19-048474-index.htm
2019-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919049310/0001104659-19-049310-index.htm
2019-09-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919051692/0001104659-19-051692-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919052662/0001104659-19-052662-index.htm
2019-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919053829/0001104659-19-053829-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919063343/0001104659-19-063343-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465919063347/0001104659-19-063347-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465919076728/0001104659-19-076728-index.htm
2020-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920000355/0001104659-20-000355-index.htm
2020-01-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920003441/0001104659-20-003441-index.htm
2020-01-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920003445/0001104659-20-003445-index.htm
2020-01-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920007733/0001104659-20-007733-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920029143/0001104659-20-029143-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920029463/0001104659-20-029463-index.htm
2020-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920030260/0001104659-20-030260-index.htm
2020-03-30NT 10-KNotification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405https://www.sec.gov/Archives/edgar/data/1614067/000110465920040377/0001104659-20-040377-index.htm
2020-04-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920043696/0001104659-20-043696-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920044707/0001104659-20-044707-index.htm
2020-04-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920044719/0001104659-20-044719-index.htm
2020-05-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920056880/0001104659-20-056880-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465920060185/0001104659-20-060185-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920060193/0001104659-20-060193-index.htm
2020-05-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1614067/000110465920060988/0001104659-20-060988-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920069867/0001104659-20-069867-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920073271/0001104659-20-073271-index.htm
2020-06-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920074205/0001104659-20-074205-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920075618/0001104659-20-075618-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920076845/0001104659-20-076845-index.htm
2020-06-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920076975/0001104659-20-076975-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920077469/0001104659-20-077469-index.htm
2020-07-28S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920086927/0001104659-20-086927-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1614067/000110465920093302/0001104659-20-093302-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920093325/0001104659-20-093325-index.htm
2020-10-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920114783/0001104659-20-114783-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920115839/0001104659-20-115839-index.htm
2020-10-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000110465920116440/0001104659-20-116440-index.htm
2020-10-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1614067/000110465920118008/0001104659-20-118008-index.htm
2018-08-13CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1614067/000135445718000309/0001354457-18-000309-index.htm
2019-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1614067/000141057819000298/0001410578-19-000298-index.htm
2018-08-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1614067/999999999518002086/9999999995-18-002086-index.htm
2019-09-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1614067/999999999519002029/9999999995-19-002029-index.htm
2018-08-14CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1614067/999999999718007242/9999999997-18-007242-index.htm